<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>UNLABELLED: BACKGROUND AND THE PURPOSE OF THE STUDY: Central Angiotensin Converting Enzyme (ACE) has an important role on cerebral microcirculation and metabolism </plain></SENT>
<SENT sid="1" pm="."><plain>However, its role in terms of protecting the brain from ischemic/reperfusion (I/R) injury are debatable </plain></SENT>
<SENT sid="2" pm="."><plain>This study evaluated the role of ACE, using enalapril as <z:chebi fb="2" ids="35457">ACE inhibitor</z:chebi>, in protection of the brain from I/R injury during transient focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> (TFCI) in normotensive rat </plain></SENT>
<SENT sid="3" pm="."><plain>METHOD: Male Sprague Dawley rats (280-320g) randomly assigned to control ischemic and enalapril pre-treated ischemic groups </plain></SENT>
<SENT sid="4" pm="."><plain>Enalapril was injected intraperitoneally 1 h before middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) at the dose of 0.03 or 0.1 mg/kg </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0002637'>Cerebral ischemia</z:hpo> was induced by 60 min MCAO followed by 24 hrs reperfusion </plain></SENT>
<SENT sid="6" pm="."><plain>After evaluation of neurological deficit scores (NDS) the animal was sacrificed for assessment of <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> and <z:hpo ids='HP_0000969'>edema</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: TFCI induced <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarctions</z:e> (283±18 mm(3)), <z:hpo ids='HP_0002181'>brain edema</z:hpo> (4.1±0.4%) and swelling (9.8±1.5%) with NDS of 3.11±0.36 </plain></SENT>
<SENT sid="8" pm="."><plain>Non-hypotensive dose of enalapril (0.03 mg/kg) improved NDS (1.37±0.26), reduced <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> (45%), <z:hpo ids='HP_0002181'>brain edema</z:hpo> (54%) and swelling of the lesioned hemispheres (34%) significantly </plain></SENT>
<SENT sid="9" pm="."><plain>However, hypotensive dose of enalapril (0.1 mg/kg) could improve neurological activity (1.67±0.31) and failed to reduce <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> (276±39 mm(3)) and swelling (10.4±1.4%) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: In the rat model of transient focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, inhibition of angiotensin converting enzyme with non-hypotensive doses of enalapril has the benefit of improving neurological activity, reducing <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e>, <z:e sem="disease" ids="C1527311" disease_type="Disease or Syndrome" abbrv="">brain swelling</z:e> and <z:hpo ids='HP_0000969'>edema</z:hpo> of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>Therefore, it is reasonable to conclude that central renin-angiotensin system may participate in ischemic/reperfusion injury of the cerebral cortex </plain></SENT>
</text></document>